Evaluation of Recombinant Human FGF-2 and PDGF-BB in Periodontal Regeneration: A Systematic Review and Meta-Analysis

Sci Rep. 2017 Mar 6;7(1):65. doi: 10.1038/s41598-017-00113-y.

Abstract

The prognosis for successful treatment of periodontal diseases is generally poor. Current therapeutic strategies often fail to regenerate infected periodontium. Recently an alternative strategy has been developed that combines conventional treatment with the application of recombinant human growth factors (rhGFs). But ambiguities in existed studies on the clinical efficacy of rhGFs do not permit either the identification of the specific growth factors effective for therapeutic interventions or the optimal concentration of them. Neither is it known whether the same rhGF can stimulate regeneration of both soft tissue and bone, or whether different patient populations call for differential use of the growth factors. In order to explore these issues, a meta-analysis was carried out. Particular attention was given to the therapeutic impact of fibroblast growth factor 2(FGF-2) and platelet derived growth factor BB (PDGF-BB). Our findings indicate that 0.3% rhFGF-2 and 0.3 mg/ml rhPDGF-BB show a greater capacity for periodontal regeneration than other concentrations and superiority to control groups with statistical significance. In the case of patients suffering only from gingival recession, however, the application of rhPDGF-BB produces no significant regenerative advantage. The findings of this study can potentially endow clinicians with guidelines for the appropriate application of these two rhGFs.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't
  • Review
  • Systematic Review

MeSH terms

  • Becaplermin
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Fibroblast Growth Factor 2 / administration & dosage*
  • Fibroblast Growth Factor 2 / pharmacology
  • Humans
  • Periodontal Diseases / drug therapy*
  • Periodontium / drug effects
  • Periodontium / physiology*
  • Proto-Oncogene Proteins c-sis / administration & dosage*
  • Proto-Oncogene Proteins c-sis / pharmacology
  • Randomized Controlled Trials as Topic
  • Recombinant Proteins / administration & dosage
  • Regeneration / drug effects*
  • Treatment Outcome

Substances

  • Proto-Oncogene Proteins c-sis
  • Recombinant Proteins
  • Fibroblast Growth Factor 2
  • Becaplermin